These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 16393626)

  • 1. [Acute cholestatic hepatitis after atorvastatin reintroduction].
    de Castro ML; Hermo JA; Baz A; de Luaces C; Pérez R; Clofent J
    Gastroenterol Hepatol; 2006 Jan; 29(1):21-4. PubMed ID: 16393626
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acute cholestatic hepatitis after reinitiating treatment with atorvastatin.
    Ridruejo E; Mandó OG
    J Hepatol; 2002 Jul; 37(1):165-6. PubMed ID: 12076881
    [No Abstract]   [Full Text] [Related]  

  • 3. Autoimmune hepatitis revealed by atorvastatin.
    Pelli N; Setti M; Ceppa P; Toncini C; Indiveri F
    Eur J Gastroenterol Hepatol; 2003 Aug; 15(8):921-4. PubMed ID: 12867804
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Severe acute cholestatic hepatitis with prolonged cholestasis and bile-duct injury following atorvastatin therapy: a case report.
    Rahier JF; Rahier J; Leclercq I; Geubel AP
    Acta Gastroenterol Belg; 2008; 71(3):318-20. PubMed ID: 19198578
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Atorvastatin-induced cholestatic hepatitis in a young woman with systemic lupus erythematosus. Grupo Lupus Virgen de las Nieves.
    Jiménez-Alonso J; Osorio JM; Gutiérrez-Cabello F; López de la Osa A; León L; Mediavilla García JD
    Arch Intern Med; 1999 Aug 9-23; 159(15):1811-2. PubMed ID: 10448788
    [No Abstract]   [Full Text] [Related]  

  • 6. Rhabdomyolysis with concurrent atorvastatin and diltiazem.
    Lewin JJ; Nappi JM; Taylor MH
    Ann Pharmacother; 2002 Oct; 36(10):1546-9. PubMed ID: 12243603
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acute hepatic injury with atorvastatin: an unusual occurrence.
    Vishwakarma P; Nehra R; Kumar A
    Indian J Pharmacol; 2014; 46(3):343-4. PubMed ID: 24987187
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug-induced liver injury associated with statins.
    Russo MW; Scobey M; Bonkovsky HL
    Semin Liver Dis; 2009 Nov; 29(4):412-22. PubMed ID: 19826975
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cholestatic jaundice induced by atorvastatin: a possible association with antimitochondrial antibodies.
    Minha S; Golzman G; Adar I; Rapoport M
    Isr Med Assoc J; 2009 Jul; 11(7):440-1. PubMed ID: 19911499
    [No Abstract]   [Full Text] [Related]  

  • 10. Hepatotoxicity associated with statins: reports of idiosyncratic liver injury post-marketing.
    Björnsson E; Jacobsen EI; Kalaitzakis E
    J Hepatol; 2012 Feb; 56(2):374-80. PubMed ID: 21889469
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tachyphylaxis and statin drugs.
    Stein JH; McBride PE
    Am J Cardiol; 2001 Mar; 87(5):674. PubMed ID: 11245286
    [No Abstract]   [Full Text] [Related]  

  • 12. Risk factors for rhabdomyolysis with simvastatin and atorvastatin.
    Golomb B; Evans M
    Drug Saf; 2006; 29(12):1191; author reply 1191-2. PubMed ID: 17147465
    [No Abstract]   [Full Text] [Related]  

  • 13. Pharmacokinetic interactions between nelfinavir and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors atorvastatin and simvastatin.
    Hsyu PH; Schultz-Smith MD; Lillibridge JH; Lewis RH; Kerr BM
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3445-50. PubMed ID: 11709322
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Severe hepatic injury associated with different statins in patients with chronic liver disease: a nationwide population-based cohort study.
    Chang CH; Chang YC; Lee YC; Liu YC; Chuang LM; Lin JW
    J Gastroenterol Hepatol; 2015 Jan; 30(1):155-62. PubMed ID: 25041076
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative safety of atorvastatin 80 mg versus 10 mg derived from analysis of 49 completed trials in 14,236 patients.
    Newman C; Tsai J; Szarek M; Luo D; Gibson E
    Am J Cardiol; 2006 Jan; 97(1):61-7. PubMed ID: 16377285
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intensive lipid lowering with atorvastatin in coronary disease.
    Ravnskov U; Rosch PJ; Sutter MC
    N Engl J Med; 2005 Jul; 353(1):93-6; author reply 93-6. PubMed ID: 16003834
    [No Abstract]   [Full Text] [Related]  

  • 17. Severe Liver Injury Associated With High-Dose Atorvastatin Therapy.
    Saha A; Garg A
    J Investig Med High Impact Case Rep; 2021; 9():23247096211014050. PubMed ID: 33966478
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intensive versus moderate lipid lowering with statins after acute coronary syndromes.
    Paradis JM; LeLorier J
    N Engl J Med; 2004 Aug; 351(7):714-7; author reply 714-7. PubMed ID: 15309744
    [No Abstract]   [Full Text] [Related]  

  • 19. Atorvastatin: a safety and tolerability profile.
    Arca M
    Drugs; 2007; 67 Suppl 1():63-9. PubMed ID: 17910522
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of alternate-day dosing versus daily dosing of atorvastatin.
    Jafari M; Ebrahimi R; Ahmadi-Kashani M; Balian H; Bashir M
    J Cardiovasc Pharmacol Ther; 2003 Jun; 8(2):123-6. PubMed ID: 12808485
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.